Innovations Taking Flight

Category
Program
MOA (Modality)
Indication
IND-Enabling
Phase 1
Phase 2
Phase 3
Approved
Status
Oncology
gp96 + CTAs (Cell Therapy)
NSCLC
End-of-Ph 2 Meeting Planning
OX40L (Cell Therapy)
Solid Tumors
Ph 1 Enrollment Complete
TNFRSF25 (mAb)
Solid Tumors
Ph 1 Enrollment Ongoing
Biodefense
gp96 + OX40L (Cell Therapy)
Multiple Indications
Platform Development
PTX-35
Antitoxin (mAb)
Anthrax
Marketing

OUR ECOSYSTEM